These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 29546612)
1. Drug-physiology interaction and its influence on the QT prolongation-mechanistic modeling study. Wiśniowska B; Polak S J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):483-490. PubMed ID: 29546612 [TBL] [Abstract][Full Text] [Related]
2. Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes. Malik M; Garnett C; Hnatkova K; Johannesen L; Vicente J; Stockbridge N J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):491-503. PubMed ID: 29651591 [TBL] [Abstract][Full Text] [Related]
3. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development. Markert M; Shen R; Trautmann T; Guth B J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956 [TBL] [Abstract][Full Text] [Related]
4. Significance of integrated in silico transmural ventricular wedge preparation models of human non-failing and failing hearts for safety evaluation of drug candidates. Kubo T; Ashihara T; Tsubouchi T; Horie M J Pharmacol Toxicol Methods; 2017; 83():30-41. PubMed ID: 27546811 [TBL] [Abstract][Full Text] [Related]
5. Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example. Wiśniowska B; Polak S J Pharm Sci; 2016 Nov; 105(11):3415-3424. PubMed ID: 27640752 [TBL] [Abstract][Full Text] [Related]
6. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428 [TBL] [Abstract][Full Text] [Related]
7. How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model. Liu G; Liu T; Cohen D; Liu T; Yan GX J Pharmacol Toxicol Methods; 2016; 81():161-70. PubMed ID: 27195944 [TBL] [Abstract][Full Text] [Related]
8. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine. Patel N; Wisniowska B; Polak S AAPS J; 2018 Jul; 20(5):83. PubMed ID: 29995258 [TBL] [Abstract][Full Text] [Related]
9. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Malik M Pacing Clin Electrophysiol; 2002 Feb; 25(2):209-16. PubMed ID: 11915990 [TBL] [Abstract][Full Text] [Related]
10. Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis. Tsamandouras N; Duvvuri S; Riley S J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):605-616. PubMed ID: 31664592 [TBL] [Abstract][Full Text] [Related]
11. Scientific white paper on concentration-QTc modeling. Garnett C; Bonate PL; Dang Q; Ferber G; Huang D; Liu J; Mehrotra D; Riley S; Sager P; Tornoe C; Wang Y J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):383-397. PubMed ID: 29209907 [TBL] [Abstract][Full Text] [Related]
12. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131 [TBL] [Abstract][Full Text] [Related]
13. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. Malik M J Cardiovasc Electrophysiol; 2001 Apr; 12(4):411-20. PubMed ID: 11332559 [TBL] [Abstract][Full Text] [Related]
14. Drugs and ventricular repolarization in a general population: the Rotterdam Study. Niemeijer MN; van den Berg ME; Franco OH; Hofman A; Kors JA; Stricker BH; Eijgelsheim M; Rijnbeek PR Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1036-41. PubMed ID: 26248883 [TBL] [Abstract][Full Text] [Related]
15. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles. Luo C; Wang K; Zhang H PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743 [TBL] [Abstract][Full Text] [Related]
16. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Funck-Brentano C; Kibleur Y; Le Coz F; Poirier JM; Mallet A; Jaillon P Circulation; 1991 Feb; 83(2):536-45. PubMed ID: 1846784 [TBL] [Abstract][Full Text] [Related]
17. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities. Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. Piotrovsky V AAPS J; 2005 Oct; 7(3):E609-24. PubMed ID: 16353940 [TBL] [Abstract][Full Text] [Related]
19. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation. Milic M; Bao X; Rizos D; Liu F; Ziegler MG Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469 [TBL] [Abstract][Full Text] [Related]
20. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). Lu HR; Yan GX; Gallacher DJ J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]